Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical ApplicationsCambridge University Press, 12/07/2013 - 608 من الصفحات With this fully revised fourth edition, Dr Stahl returns to the essential roots of what it means to become a neurobiologically empowered psychopharmacologist, expertly guided in the selection and combination of treatments for individual patients in practice. Embracing the unifying themes of 'symptom endophenotypes', dimensions of psychopathology that cut across syndromes, and 'symptoms and circuits', every aspect of the text has been updated to the frontiers of current knowledge, with the clarity of explanation and illustration that only Dr Stahl can bring. Integrating much of the basic neuroscience into the clinical chapters, and with major additions in the areas of psychosis, antipsychotics, antidepressants, impulsivity, compulsivity and addiction, this is the single most readily readable source of information on disease and drug mechanisms. This remains the essential text for all students and professionals in mental health seeking to understand and utilize current therapeutics, and to anticipate the future for novel medications. |
المحتوى
Chemical neurotransmission | 1 |
Chapter 2 Transporters receptors and enzymes as targets of psychopharmacological drug action ... | 28 |
Chapter 3 Ion channels as targets of psychopharmacological drug action | 52 |
Chapter 4 Psychosis and schizophrenia | 79 |
129 | |
Chapter 6 Mood disorders | 237 |
Chapter 7 Antidepressants | 284 |
Chapter 8 Mood stabilizers | 370 |
Chapter 10 Chronic pain and its treatment | 420 |
Chapter 11 Disorders of sleep and wakefulnessand their treatment | 444 |
Chapter 12 Attention deficit hyperactivity disorder and its treatment | 471 |
Chapter 13 Dementia and its treatment | 503 |
Chapter 14 Impulsivity compulsivity and addiction | 537 |
576 | |
591 | |
Chapter 9 Anxiety disorders and anxiolytics | 388 |
طبعات أخرى - عرض جميع المقتطفات
عبارات ومصطلحات مألوفة
abuse acid actions activity addition ADHD agents amygdala antagonist antidepressant anxiety disorders associated atypical antipsychotics behavior benzodiazepines binding bipolar disorder block brain called cause cell changes Chapter chronic circuits clinical cognitive combination D2 receptors dementia depression discussed disorder dopamine doses drugs effects efficacy enhance enzyme episodes especially excessive fear Figure function GABA gene glutamate histamine hypothetically important impulsivity increased inhibition inhibitors insomnia ion channels known lead levels linked major depressive mania mechanism monoamine mood negative neuron neurotransmitter nicotinic NMDA receptors norepinephrine normal nucleus occur pain partial agonist pathway patients pharmacologic positive possible postsynaptic potential prefrontal cortex present presynaptic problems processing properties protein receptors reduce regulate release response reuptake risk schizophrenia selective serotonin SERT shown side effects signal transduction sleep SNRI specific spectrum SSRIs stabilizers stimulation symptoms synapse Table terminal theoretically therapeutic transporter treat treatment various